Focused on innovative oncology therapies, the company has achieved global approvals and strong commercial uptake for IBTROZI in ROS1+ NSCLC, with a robust pipeline led by safusidenib for IDH1-mutant glioma. Strong cash reserves support ongoing development and expansion.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.